CSF3 and breast cancer: Two noteworthy differences in baseline characteristics were observed between patients using OBI and those not receiving G-CSF prophylaxis; most of the patients without G-CSF prophylaxis were treated with chemotherapy regimens with intermediate risk for FN albeit having at least 1 risk factor, and unlike patients in the OBI group, breast cancer was not the primary tumor type.